Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured a substantial $50 million investment.
The Gates Foundation, Novo Nordisk Foundation, and Wellcome on Wednesday announced the launch of a $50 million investment that will f
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
